The current stock price of HCWB is 2.11 USD. In the past month the price decreased by -38.37%. In the past year, price decreased by -87.28%.
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.87 | 398.69B | ||
| AMGN | AMGEN INC | 15.13 | 178.20B | ||
| GILD | GILEAD SCIENCES INC | 14.78 | 150.20B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.26 | 115.66B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.02 | 75.76B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 895.23 | 60.32B | ||
| INSM | INSMED INC | N/A | 43.91B | ||
| NTRA | NATERA INC | N/A | 33.63B | ||
| BIIB | BIOGEN INC | 10.9 | 26.76B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.37 | 20.87B | ||
| INCY | INCYTE CORP | 16.05 | 20.22B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.20B |
HCW Biologics Inc. is a biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen health span by disrupting the link between chronic, low-grade inflammation, and age-related diseases. The company is headquartered in Miramar, Florida and currently employs 36 full-time employees. The company went IPO on 2021-07-20. The company is focused on discovering and developing novel immunotherapies to lengthen the health span by disrupting the link between chronic, low-grade inflammation, and age-related diseases, such as cancer, cardiovascular diseases, diabetes, neurodegenerative diseases, autoimmune diseases, as well as other conditions. The company has developed a Tissue factOr-Based fusion (TOBI) discovery platform to generate designer, novel multi-functional fusion molecules with immunotherapeutic properties. Its lead product candidates include HCW9218 and HCW9302. HCW9218 is a clinical-stage bifunctional molecule that is designed to impact senescence by reducing senescent cells. The firm is prepared to progress HCW9218 in Phase II clinical trials for non-oncology indications.HCW9302 is designed to activate and expand regulatory T cells, which deactivate inflammasomes. Its other product candidates include HCW9201, HCW9206, HCW11-006, and others.
HCW BIOLOGICS INC
2929 N Commerce Pkwy, Miramar, Fl 33025
Miramar FLORIDA US
Employees: 36
Phone: 19548422024
HCW Biologics Inc. is a biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen health span by disrupting the link between chronic, low-grade inflammation, and age-related diseases. The company is headquartered in Miramar, Florida and currently employs 36 full-time employees. The company went IPO on 2021-07-20. The company is focused on discovering and developing novel immunotherapies to lengthen the health span by disrupting the link between chronic, low-grade inflammation, and age-related diseases, such as cancer, cardiovascular diseases, diabetes, neurodegenerative diseases, autoimmune diseases, as well as other conditions. The company has developed a Tissue factOr-Based fusion (TOBI) discovery platform to generate designer, novel multi-functional fusion molecules with immunotherapeutic properties. Its lead product candidates include HCW9218 and HCW9302. HCW9218 is a clinical-stage bifunctional molecule that is designed to impact senescence by reducing senescent cells. The firm is prepared to progress HCW9218 in Phase II clinical trials for non-oncology indications.HCW9302 is designed to activate and expand regulatory T cells, which deactivate inflammasomes. Its other product candidates include HCW9201, HCW9206, HCW11-006, and others.
The current stock price of HCWB is 2.11 USD. The price increased by 3.43% in the last trading session.
HCWB does not pay a dividend.
HCWB has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on HCWB.
HCW BIOLOGICS INC (HCWB) has a market capitalization of 5.70M USD. This makes HCWB a Nano Cap stock.
ChartMill assigns a fundamental rating of 1 / 10 to HCWB. Both the profitability and financial health of HCWB have multiple concerns.
Over the last trailing twelve months HCWB reported a non-GAAP Earnings per Share(EPS) of -28. The EPS decreased by -66.67% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -74.56% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
7 analysts have analysed HCWB and the average price target is 35.7 USD. This implies a price increase of 1591.94% is expected in the next year compared to the current price of 2.11.
For the next year, analysts expect an EPS growth of 16.94% and a revenue growth 368.22% for HCWB